 |
|
|
| |
Final analysis of a 24-week, randomized, double-blind, placebo-controlled, multicenter study of
aldafermin (NGM282) in patients with nonalcoholic steatohepatitis
|
| |
| |
AASLD 2020 Nov 11-16
Stephen A. Harrison1,2, Guy Neff3, Cynthia D. Guy4, Mustafa Bashir5, Nadege Gunn2, Angelo H. Paredes6,
Ziad Younes7, Juan P. Frias8, James F. Trotter9, Anita Kohli10, Sam E. Moussa11, Kristin Nelson12, Mildred
Gottwald12, William Chang12, Andrew Z. Yan12, Alex M. DePaoli12, Lei Ling12 and Hsiao D. Lieu12
|
| |
|
|
|
|
|
